Vorsetuzumab mafodotin
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC) . Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity[1].
Product Specifications
CAS Number
1165741-01-4
Product Name Alternative
Anti-Human CD70 Recombinant Antibody; SGN-75
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
99.69
Solubility
10 mM in DMSO
Smiles
[Vorsetuzumabmafodotin]
Molecular Weight
(150 kDa)
References & Citations
[1]M C Ryan, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010 Aug 24;103 (5) :676-84.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400054-100 1x 100 µL
HCG-beta (HCGb/54), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 